Profound develops and markets customizable, incision-free therapies for the ablation of diseased tissue. WOMEN'S HEALTH: UTERINE FIBROIDS. Find top doctors who treat Prostate Cancer near you in Provo, UT. Profound Medical's TULSA-Pro over HIFU. The total addressable market in North . Profound Medical Inc., Toronto, Ont. Raymond James 43rd Annual Institutional Investors Conference . - First Prostate Cancer Treatment Using TULSA-PRO and Philips' New Elition MR Performed in Trier, Germany - April 16, 2019 08:00 ET | Source: Profound Medical Corp. The TULSA-PRO is labeled for ablation of prostate tissue including. Profound Medical Corp ( OTC:PROF) shares have been on a sustained bull run ever since the pandemic-related market crash in March. Profound Medical Launches Prostate Cancer Trial May 2013; Profound Medical Announces Initiation of Tulsa Clinical Trial For Treatment of Localized Prostate Cancer April 2013; Chipperton departs Profound Medical May 2012; Profound Medical names Steven Plymale CEO November 2011; Profound Medical Secures $9.4 million in Venture Capital June 2011 Nature Reviews Urology (2020) Abstract. ProfoundBeliever. Profound. Profound Medical's TULSA-Pro over HIFU. profound medical ( nasdaq: prof) is sitting on top of a global ~$3.8 billion tam in the prostate cancer arena, and combined with bph ( benign prostatic hyperplasia) could reach ~$10 billion;. The TULSA-PRO medical device combines real-time MRI, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. Search doctors, conditions, or procedures . About Profound Medical Corp. Value Investing | Market insights and news of the investment gurus. Dr. Meng earned his medical degree and doctoral degree in cell and molecular biology at New York University, where he also completed a residency in urology. The PROfound trial is a prospective, biomarker-selected, phase 3 trial involving men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal . Profound Earns European Approval for Prostate Device April 22, 2016, Focused Ultrasound Foundation. . The procedure is performed in a Magnetic Resonance Imaging (MRI) suite and uses the TULSA-PRO system to ablate prostate tissue. 03, 2020 43 Comments. The procedure is performed in a Magnetic Resonance Imaging (MRI) suite and uses the TULSA-PRO system to ablate prostate . The procedure combines real-time MRI with robotically-driven directional thermal ultrasound to deliver predictable, physician-prescribed ablation of whole-gland or partial prostate tissue. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. At 3 years, functional outcomes remain good with 76% remaining free from salvage treatment. Profound Medical (NASDAQ:PROF) is sitting on top of a global ~$3.8 billion TAM in the prostate cancer arena, and combined with BPH (Benign Prostatic Hyperplasia) could reach ~$10 billion; however . We may request cookies to be set on your device. Profound is commercializing TULSA-PRO , a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. FDA clears Profound Medical's TULSA-PRO for ablation of prostate tissue Aug. 16, 2019 7:25 AM ET|About: Profound Medical Corp. (PRFMF)|By: Mamta Mayani, SA News Editor Profound Medical (OTCQX:PRFMF) has received 510(k) clearance from the FDA to market TULSA-PRO for ablation of prostate tissue. Steve Forte joining Profound is profound. Profound Medical's TULSA-PRO technology offers a new and paradigm-changing treatment for men with prostate cancer, while reducing the risks often associated with traditional treatments. ProfoundBeliever. TULSA-PRO can treat patients ranging from 1) whole-gland ablation of prostates with high-risk disease, 2) whole-gland intermediate-risk disease, 3) partial or focal prostate gland ablations, and 4). The location you tried did not return a result. About Profound Medical Corp. -01-01.png Profound Medical 2021-10-04 00:00:58 2021-09-29 15:26:42 Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation . Contact Profound Medical to set up a meeting to learn more about how our technologies can work for you. At that time, shares had slipped from a high of $20, to just $7.5,. If you have any additional questions, you can email us at info@profoundmedical.com. A NEW PARADIGM TO TREAT DISEASE Real-time Magnetic Resonance (MR) Imaging, thermal ultrasound and closed-loop temperature feedback Profound Medical is the only company to merge these three powerful modalities into customizable, incision-free therapy platforms. Learn more about Sonalleve Learn more about TULSA-PRO About the TULSA Procedure Officers

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. I have been doing research on the various prostate procedures now available on the market. About Profound Medical Corp. 42nd Annual Cowen Health Care Conference: Profound is scheduled to present virtually on Monday, March 7, 2022 at 10:30 a.m. TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE . The device is labeled for ablation of prostate tissue in the US, Canada and Europe. Prostate cancer market is big at 175k patients/y, but BPH market is huge at 10M+/y. . The word "TULSA" stands for Transurethral Ultrasound Ablation. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound Medical is a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids and palliative pain treatment in . Apr 22, 2020 8:06 PM. Get in Touch. Profound's key product is the TULSA-PRO therapeutic system, designed for precise and customizable ablation of diseased prostate tissue.

Profound Medical retires $12M debt 30-months ahead of time, saving ~$1M. Head Office. I have been told that TULSA-Pro is the gentlest form of prostate ablation available and reduces the size of the prostate by 91% on average. -01-01.png Profound Medical 2021-10-04 00:00:58 2021-09-29 15:26:42 Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation . Before joining Profound, Arun served as the Chairman and CEO of Novadaq Technologies Inc. for 13 years, guiding the company from a startup to one of the fastest growing, NASDAQ listed medical technology . LIST YOUR PRACTICE ; Dentist ; Hospital ; Pharmacy ; Search .

Profound is commercializing TULSA-PRO , a. Value investing screens and valuation tools. Apr 22, 2020 8:06 PM. TULSA-PRO is a transurethral prostate tissue ablation system that combines real-time Magnetic Resonance Imaging ("MRI") with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.

Profound Medical retires $12M debt 30-months ahead of time, saving ~$1M. The TULSA-PRO system is designed to provide customizable and predictable ablation of a surgeon defined region of prostate while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. Profound Medical (TSX:PRN; OTCQX:PRFMF) reported positive top line results from the TACT pivotal study designed to support its application to the FDA for 510(k) clearance to market TULSA-PRO in the U.S.. I have been told that TULSA-Pro is the gentlest form of prostate ablation available and reduces the size of the prostate by 91% on average. . ET. Profound Medical is the only company to merge these three powerful modalities into customizable, incision-free therapy platforms. "Profound's exciting noninvasive therapy technology has the potential to bring significant benefit to a large number of prostate cancer patients," said Baldev Ahluwalia, GE MR Beyond segment . Xiaosong Meng, M.D., Ph.D., is an Assistant Professor in the Department of Urology at UT Southwestern Medical Center specializing in prostate, kidney, testicular, and bladder cancer. Profound Medical is publicly traded on TSX (PRN) and on NASDAQ (PROF). Get in Touch. [Editor's note: Profound Medical's TULSA-PRO is the only device to merge three modalities - real-time magnetic resonance imaging, direct and controlled thermal ultrasound and close-loop temperature feedback - into a customized, incision-free ablation of prostate tissue while actively protecting the urethra and rectum to help preserve a .

Profound Medical, The Apple Of The Prostate Arena TJ Roberts Fri, Apr. GMP starts Profound Medical at speculative buy AUA Happy Hour. News. Profound Medical is developing an interventional, MRI-guided, trans-urethral ultrasound device to treat prostate cancer. WOMEN'S HEALTH: UTERINE FIBROIDS. Please enter a valid 5-digit Zip Code. Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy. Profound Medical has initiated commercialization of its TULSA-PRO system. I have been doing research on the various prostate procedures now available on the market. Profound Medical has developed a non-invasive device used to treat prostate cancer and benign prostate hyperplasia (BPH). Profound Medical (TSX:PRN; OTCQX:PRFMF) received FDA clearance to market TULSA-PRO for the ablation of prostate tissue, with an FDA label allowing U.S. surgeons to perform procedures on both malignant and benign tissue.. TULSA-PRO is a transurethral prostate tissue ablation system that uses real-time MRI, robotically-driven directional thermal ultrasound and closed-loop temperature feedback . If you have any additional questions, you can email us at info@profoundmedical.com. 106893A. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website. Prostate cancer market is big at 175k patients/y, but BPH market is huge at 10M+/y. 106893A. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Find a doctor near you. Profound is commercializing TULSA-PRO , a novel technology.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. [Editor's note: Profound Medical's TULSA-PRO is the only device to merge three modalities - real-time magnetic resonance imaging, direct and controlled thermal ultrasound and close-loop temperature feedback - into a customized, incision-free ablation of prostate tissue while actively protecting the urethra and rectum to help preserve a . 2400 Skymark Avenue, Unit 6 Mississauga, ON Canada L4W 5K5. MRI-guided transurethral ultrasound ablation is an exciting, minimally invasive technology with the potential to provide targeted ablation of prostate cancer tissue. Book an appointment today! Profound Medical: Non-Surgical Prostatectomy Is Profound Osmium Research Mon, Feb. 03, 2020 51 Comments. The TULSA Procedure is a minimally invasive procedure that uses directional ultrasound to produce very high temperatures to ablate targeted prostate tissue.